Amgen (NASDAQ: AMGN) is presenting new data from its oncology pipeline at the European Society for Medical Oncology (ESMO) Congress 2024, held in Barcelona from September 13-17. The data includes Amgen-sponsored and investigator-sponsored studies focusing on molecularly targeted modalities for colorectal, lung, prostate, and gastric cancers.
Jay Bradner, M.D., Executive Vice President, Research and Development, and Chief Scientific Officer at Amgen, stated, "The breadth of these data reflects our strategy to advance diverse modalities for difficult-to-treat cancers. These ESMO results underscore our leadership in oncology, contributing significant advancements with both investigational and established therapies. Guided by a deep understanding of cancer biology and leveraging incisive therapeutics, we can target dominant drivers of disease with unprecedented precision."
Combination Therapy for Metastatic Colorectal Cancer
First findings from the Phase 1b CodeBreaK 101 study of LUMAKRAS® (sotorasib) plus Vectibix® (panitumumab) in combination with FOLFIRI in first-line patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC) are being presented. Colorectal cancer (CRC) is the second leading cause of cancer deaths worldwide, accounting for 10% of all cancer diagnoses. KRAS mutations are common in colorectal cancers, with the KRAS G12C mutation present in approximately 3-5% of cases.
Novel PRMT5 Inhibitor for MTAP-Deleted Solid Tumors
Phase 1 dose escalation and initial dose expansion data from AMG 193, an MTA-cooperative PRMT5 inhibitor, were selected for a presidential symposium session. This study focuses on patients with MTAP-deleted solid tumors, representing a targeted approach to cancers with specific genetic deletions.
First-in-Human Study of Xaluritamig in Prostate Cancer
The first-in-human study of xaluritamig in men with metastatic castration-resistant prostate cancer (mCRPC) is being presented. This research explores a novel therapeutic approach for prostate cancer, which remains a significant cause of mortality in men worldwide.
Sotorasib Clinical Outcomes in NSCLC
Long-term clinical outcomes of sotorasib in pre-treated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC) are being presented as a pooled analysis from the CodeBreaK clinical trials. Lung cancer is the leading cause of cancer-related deaths globally, with KRAS G12C being the most common KRAS mutation in NSCLC, found in about 13% of non-squamous NSCLC patients.
Biomarker Analysis in Gastric Cancer
Data on fibroblast growth factor receptor 2 isoform IIIb (FGFR2b) protein overexpression and biomarker overlap in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC) for bemarituzumab are being presented. Gastric cancer remains a significant global health challenge, and identifying predictive biomarkers is crucial for targeted therapies.
Investigator-Sponsored Studies on Vectibix
Several investigator-sponsored studies on Vectibix (panitumumab) are also part of the presentations, including mRNA profiling as a biomarker of prognosis and response to first-line treatment in metastatic colorectal cancer and circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer.
